Myotonic Dystrophy Treatment in Hyderabad: The Most Common Adult Muscular Dystrophy — and Why the Heart Must Be Monitored from Day One

The pattern you are describing — stiffness that is worst after rest and improves with repeated movement — is called the warm-up phenomenon of myotonia, and it is a characteristic feature of both Myotonic Dystrophy and Myotonia Congenita. In Myotonic Dystrophy, the myotonia (muscle stiffness) is accompanied by progressive muscle weakness and the multi-system involvement described on this page. In Myotonia Congenita, stiffness is the dominant problem and progressive weakness is not typically a feature. The distinction requires clinical assessment and EMG at KIMS. Please call 040-44885000 — an EMG with myotonic discharge recording and a genetic blood test will give you a specific answer, usually within one appointment.

This is one of the most important questions for any DM1 patient facing surgery — and the answer requires careful specialist preparation rather than a simple yes or no. DM1 patients face real anaesthetic risks: prolonged respiratory weakness after intubation, cardiac arrhythmias triggered by anaesthetic agents, myotonic reactions to succinylcholine (which must be avoided), and unusual sensitivity to sedatives and opioids. These risks can be managed well with the right preparation. At KIMS, we provide a pre-anaesthetic neuromuscular assessment, a written anaesthetic risk alert letter for your surgical team, recommendations on which agents to use and avoid, and a plan for post-operative respiratory monitoring. Please contact KIMS Neuroscience — call 040-44885000 — well in advance of any planned surgical procedure so this preparation can be arranged.

Yes — absolutely. A normal ECG at the time of DM1 diagnosis does not mean cardiac risk has been excluded. Cardiac conduction disease in DM1 is progressive and often silent — patients can develop significant heart block, arrhythmias, or ventricular dysfunction over subsequent years without any cardiac symptoms whatsoever. The first sign of cardiac disease in some DM1 patients is a blackout (syncope from heart block) or sudden death. Annual ECG and 24-hour Holter monitoring are recommended lifelong from the time of DM1 diagnosis in all published guidelines, regardless of cardiac symptoms. Please contact KIMS Neuroscience — call 040-44885000 — if your annual cardiac review is overdue.

Yes — this is the phenomenon of anticipation, and it is one of the most important features of Myotonic Dystrophy genetics. The CTG repeat expansion in DM1 is unstable when it is copied from parent to child during reproduction, and it tends to grow — sometimes dramatically so. A parent with a moderate expansion and adult-onset disease may transmit a much larger expansion to their child, resulting in childhood-onset or even congenital DM1. The largest expansions (more than 1,000 CTG repeats) cause congenital DM1 — the most severe form, presenting at birth with severe hypotonia and respiratory failure. This is why genetic testing of the child to determine their specific repeat size is recommended at KIMS, and why genetic counselling before future pregnancies is strongly advised. Please call 040-44885000 to arrange a genetic counselling appointment.

Your sister should be assessed and tested at KIMS urgently — for two reasons. First, if she has DM1, she has the same cardiac risk that you carry, and cardiac monitoring should begin immediately. Second, if she is planning pregnancy, she needs to understand the reproductive implications before conception. Because DM1 is autosomal dominant, each first-degree relative of a confirmed DM1 patient has a 50% probability of carrying the same mutation. At KIMS, cascade genetic testing for at-risk family members is available and is actively recommended to all DM1 patients at the time of their diagnosis. Please ask your sister to call 040-44885000 and mention that she is a first-degree relative of a confirmed DM1 patient — this will expedite her appointment.

As of 2025, there is no approved disease-modifying treatment that corrects the underlying genetic defect or halts progression in Myotonic Dystrophy. However, the research landscape is very active. RNA-targeting approaches — antisense oligonucleotides (ASOs) that neutralise the toxic CUG repeat RNA — have shown promising results in preclinical models and are in early-phase clinical trials. Gene-editing approaches including CRISPR-Cas9 are being investigated. Small molecule compounds that disrupt the sequestration of MBNL1 by the toxic RNA are in development. While these treatments are not yet available outside clinical trials, the pace of progress is substantial. At KIMS, patients are informed about the current research landscape and, where relevant, are connected with clinical trial networks through KIMS's academic partnerships. Call 040-44885000 to discuss the current options.

Hypersomnia — excessive daytime sleepiness — is one of the most disabling non-muscular symptoms of DM1 and is frequently underestimated by clinicians who focus only on the motor features. It arises from a combination of central nervous system involvement (dysfunction of sleep-wake regulation centres in the brain) and sleep-disordered breathing (obstructive sleep apnoea and central apnoea from respiratory muscle and respiratory control abnormalities). The first step at KIMS is a formal sleep study to determine whether sleep-disordered breathing is contributing — if so, CPAP or BiPAP therapy significantly improves daytime alertness in most patients. For the central hypersomnia component, modafinil has been used as a wakefulness-promoting agent and has evidence in DM1 specifically. This symptom deserves treatment — falling asleep at work, while driving, or caring for children is a serious safety issue. Please discuss it with your KIMS specialist at 040-44885000.